Sequana Medical NV: Sequana Medical announces strong top-line results from RED DESERT alfapump DSR study and expansion of DSR development programme
-
s
improvement in diuretic
Conference call with
Euronext Brussels: SEQUA
), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive top-line results from the RED DESERT study with repeated dose
alfapump DSR
SAHARA DESERT, the study of the
alfapump DSR in diuretic-resistant heart failure patients with residual congestion is on track to start before the end of this quarter, with interim results expected before year-end and top-line results expected in H2 2022.